Company has already coverted these TCRs to reagents using its STAR technology.

Altor BioScience licensed T-cell receptors (TCRs) specific for cells infected by HIV and HCV from Massachusetts General Hospital (MGH). Altor has been collaborating with MGH and has reportedly already improved and converted the licensed TCRs into targeted therapeutic reagents.


The transaction covers the exclusive, worldwide rights to develop and commercialize drugs based on these TCRs. The compounds will be added to Altor’s STAR™ program, The company’s STAR technology, or Soluble T-cell Antigen Receptor technology, is designed to produce biologically active, soluble TCR molecules in a single-chain format.


The company has two clinical-stage drugs. Its staph treatment is in Phase III trials, and the anticancer agent is in a Phase I/IIa study.

Previous articleResearchers Implicate RUNX3 in Early-Stage Colon Cancer
Next articleGSK Initially Tenders About $25M to Cellzome in Billion-Dollar Deal